SynthesisFrontiers in pediatrics2026
Efficacy and safety of monoclonal antibodies against respiratory syncytial virus disease in premature infants: a systematic review and network meta-analysis.
Synthesis in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection (LRTI) in infants and young children, which may progress to bronchiolitis, pneumonia, and other severe respiratory complications. This study aimed to evaluate the efficacy and safety of monoclonal antibodies (mAbs) against the RSV disease in premature infants. Methods: A comprehensive literature search was conducted across the PubMed, Cochrane Library, and Embase databases from inception through December 2025. Statistical analyses were performed using STATA software (version 15.0). Effect estimates were expressed as relative risk (RR) with corresponding 95% confidence intervals, and treatment rankings were evaluated using the surface under the cumulative ranking curve (SUCRA) probability. Results: This Network Meta-analysis (NMA) included 7 randomized controlled trials involving 4 drugs and 11319 infants. Compared with the placebo, nirsevimab, motavizumab, and palivizumab have shown beneficial effects at reducing RSV-related hospitalization rates (RR, nirsevimab: 0.20, 95% CI: 0.09-0.45; motavizumab: 0.32 95% CI: 0.19-0.53; palivizumab: 0.43; 95% CI: 0.30-0.61) and Intensive Care Unit (ICU) admissions due to RSV infections (nirsevimab: 0.09, 95% CI: 0.01-0.87; motavizumab: 0.23, 95% CI: 0.08-0.65; palivizumab: 0.43, 95% CI: 0.21-0.90) in preterm infants. Nirsevimab was most likely to exert the best therapeutic effects, with the highest (SUCRA) values of 94.4% for RSV-related hospitalization rates and 89.1% for ICU admissions. No significant differences were found in mechanical ventilation use, deaths related to RSV Infections and drug-related adverse events. Conclusion: Nirsevimab, motavizumab, and palivizumab all reduced RSV-related hospitalizations and ICU admissions in preterm infants, with nirsevimab showing the greatest effect. However, further studies are needed to confirm these findings. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024583222, identifier CRD42024583222.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.